Dilarof 500mcg

Tablet
Pack Size :   10 Tablet x 1 strip
Generics :   Roflumilast
Best Price * TK  200.00
* Delivery will be done in Dhaka city only.

Alternative Product


More Information About - Dilarof 500mcg

Description

Generic Name

Roflumilast

Precaution

Roflumilast is not a bronchodilator and should not be used for the treatment of a sudden attack of breathlessness. Patients treated with this drug should have their weight monitored regularly. If unexplained or clinically significant weight loss occurs, this should be evaluated, and discontinuation of Roflumilast should be considered. Roflumilast should be given with caution in patients with severe immunological diseases (HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy and others), severe acute infectious diseases (tuberculosis or acute hepatitis), cancer (except basal-cell carcinoma), and severe impairment of the heart function. Lactation: Probable that roflumilast, its metabolites, or both are excreted into milk; avoid use

Indication

Chronic obstructive pulmonary disease

Contra Indication

Roflumilast is contraindicated to patients with a history of hypersensitivity to Roflumilast or any of other ingredients of the tablet and if a patient has moderate to severe liver impairment.

Dose

N/A

Side Effect

1-10% Diarrhea (9.5%),Weight loss (7.5%),Nausea (4.7%),Headache (4.4%),Back pain (3.2%),Insomnia (2.4%),Decreased appetite (2.1%),Dizziness (2.1%) 1-10% Abdominal pain (1-2%),Anxiety (1-2%),Depression (1-2%),Dyspepsia (1-2%),Gastritis (1-2%),Muscle spasms (1-2%),Rhinitis (1-2%),Sinusitis (1-2%),Tremor (1-2%),Urinary tract infection (1-2%),Vomiting (1-2%) Frequency Not Defined Suicidality

Pregnancy Category

Name : Not Classified
Description
FDA has not yet classified the drug into a specified pregnancy category.

Mode of Action

Selective phosphodiesterase (PDE)-4 inhibitor; PDE-4 inhibition leads to accumulation of intracellular cyclic adenosine monophosphate (cAMP) in lung tissue and is thought to be underlying mechanism of action.

Interaction

Erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine; rifampicin, phenobarb, carbamazepine, phenytoin, theophylline, OC.

Pregnancy Category Note

Pregnancy Data are not available regarding use in pregnant women Lactation Probable that roflumilast, its metabolites, or both are excreted into milk; avoid use

Adult Dose

Chronic Obstructive Pulmonary Disease Reduction of frequency of exacerbations or worsening of symptoms 500 mcg PO once daily

Child Dose

Safety and efficacy not established

Renal Dose

N/A

Administration

N/A

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.

Others Product

In Stock
Inhalation Aroflo - 250/25 HFA Inhaler Salmeterol + Fluticasone Aristopharma Limited
Tk 795
In Stock
Tablet Veracal SR 240 mg Tab Verapamil Incepta Pharmaceuticals Ltd.
Tk 70
In Stock
Prescribed
Tablet Canazole - 50mg Fluconazole ACI Limited
Tk 80.5
In Stock
Tablet Dophylin - 400mg Doxofylline Acme Laboratories Ltd.
Tk 80